AnGes, Inc. Logo

AnGes, Inc.

Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.

4563 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnGes, Inc., founded in 1999, is a biopharmaceutical company dedicated to the research and development of gene-based medicines. The company focuses on becoming a global leader in genetic pharmaceuticals by developing innovative treatments that harness the power of genes. Its core pipeline includes Hepatocyte Growth Factor (HGF) gene therapy products for blood vessel regeneration, DNA vaccines based on plasmid DNA technology, and NF-kB decoy oligonucleotides. AnGes actively engages in clinical studies and forms global alliances and manufacturing collaborations to advance its therapeutic programs and make novel treatments accessible to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 06:50
Interim Report
確認書
Japanese 8.9 KB
2025-08-13 04:19
Interim Report
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese 488.0 KB
2025-03-31 04:52
Regulatory News Service
臨時報告書
Japanese 25.5 KB
2025-03-31 03:22
Governance Information
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese 23.7 KB
2025-03-31 03:18
Registration Form
確認書
Japanese 8.9 KB
2025-03-31 03:17
Registration Form
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2024-09-03 06:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 203.2 KB
2024-08-30 09:06
Registration Form
有価証券届出書(参照方式)
Japanese 381.2 KB
2024-08-14 02:28
Interim Report
確認書
Japanese 8.9 KB
2024-08-14 02:27
Interim Report
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese 725.7 KB
2024-05-14 02:27
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-05-14 02:25
Quarterly Report
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese 457.7 KB
2024-03-29 01:45
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2024-03-29 01:43
Governance Information
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese 23.6 KB
2024-03-29 01:39
Registration Form
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.